Please confirm you are human

This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.

A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.

Hold with a pointer, or hold Space or Enter.

News


markets.businessinsider.com > news > stocks > santa-ana-bio-announces-first-subjects-dosed-in-phase-1-study-of-sab01-to-treat-autoimmune-inflammatory-diseases-1036542739

Santa Ana Bio Announces First Subjects Dosed in Phase 1 Study of SAB01 to Treat Autoimmune Inflammatory Diseases

17+ hour, 46+ min ago   (402+ words) First-in-class bispecific antibody designed for mast cell elimination without the safety issues associated with current KIT therapeuticsPhase 1 si... Santa Ana Bio Announces First Subjects Dosed in Phase 1 Study of SAB01 to Treat Autoimmune Inflammatory Diseases - First-in-class bispecific antibody designed for mast…...


finance.yahoo.com > healthcare > articles > methodsense-launches-luminlogic-nextgen-transform-130000016.html

MethodSense Launches LuminLogic NextGen to Transform MedTech Compliance

12+ hour, 55+ min ago   (236+ words) AI-Enabled Platform Embeds 25+ Years of Regulatory and Quality Expertise to Accelerate Product Commercialization RALEIGH, N.C., Sept. 14, 2026 /PRNewswire/ -- Today MethodSense® announced the launch of LuminLogic® NextGen, a new AI-enabled quality and regulatory compliance platform that unifies eQMS, regulatory intelligence, submission readiness, and…...


thehindubusinessline.com > companies > piramal-pharmas-uk-facility-receives-7-observations-from-us-fda-inspection > article71466358.ece

Piramal Pharma Morpeth facility gets 7 US FDA observations

1+ hour, 44+ min ago   (151+ words) Piramal Pharma’s Morpeth facility in the UK received seven observations following a US FDA inspection conducted from September 3 to 11. Piramal Pharma Limited's Morpeth facility in the UK has received seven observations after an inspection by the US Food and Drug…...


eurohealthobservatory.who.int > news-room > events > item > 09/22/2026 > default-calendar > promoting-affordable-access-to-new-medicines-a-state-of-health-in-the-eu-webinar

Promoting affordable access to new medicines: a State of Health in the EU webinar

10+ hour, 10+ min ago   (115+ words) Access to medicines is under pressure across the EU, as rising prices for new therapies and growing demand test the limits of public budgets. Between 2020 and 2025, Member States implemented wide-ranging reforms to expand coverage, reduce out-of-pocket costs, and sustain innovation....


kalkinemedia.com > au > news > announcements > regal-partners-increases-stake-in-oncosil-medical-to-1382-following-multiple-transactions

Regal Partners Increases Stake in OncoSil Medical to 13.82% Following Multiple Transactions

11+ hour, 28+ min ago   (69+ words) Kalkine Media OncoSil Medical (ASX:OSL) OSL (ASX:OSL) announced a change in substantial holder interests from Regal Partners Funds Management Pty Limited and its associates, revealing their voting power rose from 9.25% to 13.82%. This is based on the total shares…...


sg.news.yahoo.com > us-push-cut-drug-prices-050321449.html

US push to cut drug prices could mean longer waits for European patients

13+ hour, 52+ min ago   (942+ words) Last May, US President Donald Trump pushed to align drug pricing with the lowest levels among other developed nations — so-called most-favoured-nation (MFN) pricing. However, the pricing policy might have negative consequences. European patients might have to wait longer for some…...


marketscreener.com > news > otsuka-arm-s-lung-cancer-drug-plus-chemotherapy-trial-shows-six-month-median-pfs-benefit-ce785bdcd88cf32d

Otsuka Arm's Lung Cancer Drug Plus Chemotherapy Trial Shows Six-Month Median PFS Benefit

13+ hour, 47+ min ago   (41+ words) marketscreener.com Otsuka Holdings Co., Ltd. Otsuka Arm's Lung Cancer Drug Plus Chemotherapy Trial Shows Six-Month Median PFS Benefit Published on 09/14/2026 at 01:08 am EDT...


weforum.org > publications > the-system-is-not-the-patient-next-steps-for-implementing-outcome-based-care

The System Is Not the Patient

14+ hour, 41+ min ago   (316+ words) Across OECD countries, healthcare spending has long grown faster than GDP, while health-adjusted life expectancy has stagnated or declined and up to 20% of spending remains directed to low-value care. Outcome-based care measures success by patient outcomes relative to resources used,…...


pharmadispatch.com > news > melbourne-biotechs-psychedelic-infusion-keeps-binge-eating-disorder-at-bay-three-months-after-tr

Entropy's psychedelic infusion keeps binge eating disorder at bay three months after treatment ends

15+ hour, 41+ min ago   (131+ words) PharmaDispatch Entropy's psychedelic infusion keeps binge eating disorder at bay three months after treatment ends Six patients who had lived with binge eating disorder for as long as two decades sat down for two infusions of an experimental psychedelic drug....


sheppnews.com.au > news > committee-concerned-cancer-cuts-will-cost-lives

Committee concerned cancer cuts will cost lives

15+ hour, 55+ min ago   (737+ words) Federal Government plans to stop funding its Prostate Cancer Specialist Nursing Program could cost lives, particularly in rural and regional areas, says Shepparton’s Biggest Ever Blokes Lunch Committee. The government announced on August 31 its intention to end funding for the…...